April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
A Novel Dendrimer Formulation for Enhanced Solubility and Delivery of Gatifloxacin, Ketorolac Tromethamine, and Tropicamide
Author Affiliations & Notes
  • C. Durairaj
    Dept of Pharmaceutical Sciences, Univ of Colorado Denver, Aurora, Colorado
  • P. Tyagi
    Dept of Pharmaceutical Sciences, Univ of Colorado Denver, Aurora, Colorado
  • J. Chandler
    Chandler and Chandler LLC, Verona, Wisconsin
  • U. Kompella
    Dept of Pharmaceutical Sciences, Univ of Colorado Denver, Aurora, Colorado
  • Footnotes
    Commercial Relationships  C. Durairaj, Visionary Therapeutics Corporation, Richmond, VA, F; P. Tyagi, Visionary Therapeutics Corporation, Richmond, VA, F; J. Chandler, Visionary Therapeutics Corporation, Richmond, VA, F; U. Kompella, Visionary Therapeutics Corporation, Richmond, VA, F.
  • Footnotes
    Support  Visionary Therapeutics Corporation, Richmond, VA
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2421. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Durairaj, P. Tyagi, J. Chandler, U. Kompella; A Novel Dendrimer Formulation for Enhanced Solubility and Delivery of Gatifloxacin, Ketorolac Tromethamine, and Tropicamide. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2421.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Cell penetrating dendrimeric polyguanidilyated translocators (DPTs), a new class of polymers, potentially enhance topical ocular delivery across epithelial barriers. Ophthalmic drop dosage forms require high drug solubility. The study objective was to determine whether a g6 DPT dendrimer is suitable for enhancing the solubility of gatifloxacin (zwitterion), ketorolac tromethamine (KT, negatively charged), and tropicamide (positively charged), three topical ophthalmic drugs.

Methods: : Equilibrium drug solubility studies in the presence of 1 and 10 mg/ml dendrimer were carried out in isotonic PBS (pH 5.65, 6.30, and 7.37) using HPLC analysis. Drug and dendrimer interactions were characterized using isothermal titration calorimetry (ITC) and Fourier-transformed infrared spectroscopy (FTIR). Molecular size of the dendrimer was ensured using membrane filtration.

Results: : The dendrimer was highly soluble (> 200 mg/ml) at all pH conditions and permeated completely through a 3,000 MW cutoff membrane, indicating that its molecular, nano-form. The dendrimer increased the solubility of all three drugs in a pH dependent manner. The maximum solubility increase was 2.8-, 2-, and 1.8-fold, respectively, for gatifloxacin (pH 6.3), KT (5.65), and tropicamide (pH 5.65). ITC studies revealed >1 stoichiometry of gatifloxacin:dendrimer association. Competitive ITC inhibition studies in the presence of sodium chloride or Triton-X confirmed ionic and hydrophobic interactions, respectively, in gatifloxacin-dendrimer binding. FTIR studies confirmed ionic interactions (between guanidine groups of dendrimer and carboxylic group of gatifloxacin) and hydrogen bonding (between amide bonds in branching units of dendrimer and electronegative atoms in gatifloxacin) in the complex. FTIR analysis indicated hydrogen bond based interactions for KT and tropicamide with dendrimer.

Conclusions: : Dendrimer increases solubility of all three drugs and is capable of participating in ionic, hydrophobic, or hydrogen bonds with drug molecules. DPT g6 dendrimer is a new nanosystem that might allow enhanced drug solubility as well as delivery.

Keywords: development 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×